june 2024, september 2024, beam therapeutics, cancer, cardiovascular diseases, crispr therapeutics, crispr-cas9 technology, drug development (pharmacology), enzyme-linked immunosorbent assay, genetic diseases, genome editing, insights, issue no. 6, issue no. 9, mass spectrometry, sickle cell disease, t-cell immunotherapy, topics, vertex pharmaceuticals, volume 44